Contribution of glucocorticoid-mineralocorticoid receptor pathway on the obesity-related adipocyte dysfunction

Biochemical and Biophysical Research Communications

Volumn 419, Issue 2, 2012, Pages 182-187

  Hirata, Ayumu ^a   Maeda, Norikazu ^a   Nakatsuji, Hideaki ^a   Hiuge Shimizu, Aki ^a   Okada, Takuya ^a   Funahashi, Tohru ^a   Shimomura, Iichiro ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Adiponectin; Glucocorticoid; Mineralocorticoid receptor; Obesity; Oxidative stress

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; ACETYLCYSTEINE; ADIPOCYTOKINE; ADIPONECTIN; EPLERENONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HYDROGEN PEROXIDE; MESSENGER RNA; MIFEPRISTONE; MINERALOCORTICOID RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SMALL INTERFERING RNA;

ABDOMINAL SURGERY; ADIPOCYTE; ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY FAT DISTRIBUTION; BODY MASS; CONTROLLED STUDY; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAABDOMINAL FAT; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; 3T3-L1 CELLS; ADIPOCYTES; ADIPOKINES; ANIMALS; BODY MASS INDEX; GLUCOCORTICOIDS; HUMANS; MALE; METABOLIC NETWORKS AND PATHWAYS; MICE; MICE, MUTANT STRAINS; MIFEPRISTONE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; OBESITY; RECEPTORS, GLUCOCORTICOID; RECEPTORS, MINERALOCORTICOID; RNA, SMALL INTERFERING; SPIRONOLACTONE;

MUS;

EID: 84857992329     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.01.139     Document Type: Article

References (24)

1. Matsuzawa Y., Funahashi T., Kihara S., Shimomura I. Adiponectin and metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 2004, 24:29-33.
2. Furukawa S., Fujita T., Shimabukuro M., Iwaki M., Yamada Y., Nakajima Y., Nakayama O., Makishima M., Matsuda M., Shimomura I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest. 2004, 114:1752-1761.
3. Hirata A., Maeda N., Hiuge A., Hibuse T., Fujita K., Okada T., Kihara S., Funahashi T., Shimomura I. Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovasc. Res. 2009, 84:164-172.
4. Guo C., Ricchiuti V., Lian B.Q., Yao T.M., Coutinho P., Romero J.R., Li J., Williams G.H., Adler G.K. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation 2008, 117:2253-2261.
5. Funder J., Myles K. Exclusion of corticosterone from epithelial mineralocorticoid receptors is insufficient for selectivity of aldosterone action: in vivo binding studies. Endocrinology 1996, 137:5264-5268.
6. Funder J.W. Mineralocorticoid receptors: distribution and activation. Heart Fail. Rev. 2005, 10:15-22.
7. Bujalska I.J., Kumar S., Stewart P.M. Does central obesity reflect " cushing's disease of the omentum" ?. Lancet 1997, 349:1210-1213.
8. Maeda N., Takahashi M., Funahashi T., Kihara S., Nishizawa H., Kishida K., Nagaretani H., Matsuda M., Komuro R., Ouchi N., Kuriyama H., Hotta K., Nakamura T., Shimomura I., Matsuzawa Y. PPAR gamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001, 50:2094-2099.
9. Kurata A., Nishizawa H., Kihara S., Maeda N., Sonoda M., Okada T., Ohashi K., Hibuse T., Fujita K., Yasui A., Hiuge A., Kumada M., Kuriyama H., Shimomura I., Funahashi T. Blockade of Angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int. 2006, 70:1717-1724.
10. Hitomi H., Kiyomoto H., Nishiyama A., Hara T., Moriwaki K., Kaifu K., Ihara G., Fujita Y., Ugawa T., Kohno M. Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells. Hypertension 2007, 50:750-755.
11. Moore X.L., Tan S.L., Lo C.Y., Fang L., Su Y.D., Gao X., Woodcock E.A., Summers R.J., Tregear G.W., Bathgate R.A., Du X.J. Relaxin antagonizes hypertrophy and apoptosis in neonatal rat cardiomyocytes. Endocrinology 2007, 148:1582-1589.
12. Pearce D. The role of SGK1 in hormone-regulated sodium transport. Trends Endocrinol. Metab. 2001, 12:341-347.
13. Shimizu N., Yoshikawa N., Ito N., Maruyama T., Suzuki Y., Takeda S., Nakae J., Tagata Y., Nishtani S., Takehara K., Sano M., Fukuda K., Suematsu M., Morimoto C., Tanaka H. Crosstalk between glucocorticoid receptor and nutritional sensor mTOR in skeletal muscle. Cell Metab. 2011, 13:170-182.
14. Engeli S., Bohnke J., Feldpausch M., Gorzelniak K., Heintze U., Janke J., Luft F.C., Sharma A.M. Regulation of 11β-HSD genes in human adipose tissue: influence of central obesity and weight loss. Obes. Res. 2004, 12:9-17.
15. Wake D.J., Rask E., Livingstone D.E., Söderberg S., Olsson T., Walker B.R. Local and systemic impact of transcriptional up-regulation of 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity. J. Clin. Endocrinol. Metab. 2003, 88:3983-3988.
16. Lindsay R.S., Wake J.W., Saraswathy N., Bunt J., Livingstone D.E.W., Permana P.A., Tataranni P.A., Walker B.R. Subcutaneous adipose 11β-hydroxysteroid dehydrogenase type 1 activity and messenger ribonucleic acid levels are associated with adiposity and insulinemia in Pima Indians and Caucasians. J. Clin. Endocrinol. Metab. 2003, 88:2738-2744.
17. Masuzaki H., Paterson J., Shinyama H., Morton N.M., Mullins J.J., Seckl J.R., Flier J.S. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001, 294:2166-2170.
18. Masuzaki H., Yamamoto H., Kenyon C.J., Elmquist J.K., Morton N.M., Paterson J.M., Shinyama H., Sharp M.G., Fleming S., Mullins J.J., Seckl J.R., Flier J.S. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J. Clin. Invest. 2003, 112:83-90.
19. Young M.J., Morgan J., Brolin K., Fuller P.J., Funder J.W. Activation of mineralocorticoid receptors by exogenous glucocorticoids and the development of cardiovascular inflammatory responses in adrenalectomized rats. Endocrinology 2010, 151:2622-2628.
20. Rafiq K., Nakano D., Ihara G., Hitomi H., Fujisawa Y., Ohashi N., Kobori H., Nagai Y., Kiyomoto H., Kohno M., Nishiyama A. Effects of mineralocorticoid receptor blockade on glucocorticoid-induced renal injury in adrenalectomized rats. J. Hypertens. 2011, 29:290-298.
21. + retention in man is not mediated by the mineralocorticoid receptor. J. Clin. Endocrinol. Metab. 1991, 72:1060-1066.
22. Bailey M.A., Mullins J.J., Kenyon C.J. Mineralocorticoid and glucocorticoid receptors stimulate epithelial sodium channel activity in a mouse model of Cushing syndrome. Hypertension 2009, 54:890-896.
23. Funder J.W. Glucocorticoid and mineralocorticoid receptors, Biology and Clinical Relevance. Annu. Rev. Med. 1997, 48:231-240.
24. Hiuge-Shimizu A., Maeda N., Hirata A., Nakatsuji H., Nakamura K., Okuno A., Kihara S., Funahashi T., Shimomura I. Dynamic changes of adiponectin and S100A8 levels by the selective peroxisome proliferator-activated receptor-gamma agonist rivoglitazone. Arterioscler. Thromb. Vasc. Biol. 2011, 31:792-799.